WT1 peptide vaccine, one of the most promising cancer vaccines: Its present status and the future prospects

Immunotherapy

Volumn 2, Issue 5, 2010, Pages 591-594

  Oka, Yoshihiro ^a   Sugiyama, Haruo ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

cancer antigen; peptide vaccine; WT1

Indexed keywords

CYCLOPHOSPHAMIDE; GEMCITABINE; IMATINIB; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; EDITORIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; LEUKEMIA; LUNG NON SMALL CELL CANCER; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SUBUNIT; WT1 PROTEINS;

EID: 77957606218     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.58     Document Type: Editorial

References (24)

1. Oka Y, Tsuboi A, Oji Y et al.: WT1 peptide vaccine for the treatment of cancer. Curr. Opin. Immunol. 20(2), 211-220 (2008).
2. Oka Y, Tsuboi A, Fujiki F et al.: "Cancer antigen WT1 protein-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide. Curr. Med. Chem. 15(29), 3052-3061 (2008).
3. Cheever MA, Allison JP, Ferris AS et al.: The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15(17), 5323-5337 (2009).
4. Saito Y, Kitamura H, Hijikata A et al.: Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci. Transl. Med. 2, 17RA9 (2010).
5. Elisseeva OA, Oka Y, Tsuboi A et al.: Humoral immune responses against Wilms' tumor gene WT1 product in patients with hematopoietic malignancies. Blood 99(9), 3272-3279 (2002).
6. Oji Y, Kitamura Y, Kamino E et al.: WT1 IgG antibody for early detection of non-small cell lung cancer and as its prognostic factor. Int. J. Cancer 125(2), 381-387 (2009).
7. Tamura H, Dan K, Yokose N et al.: Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes. Leuk. Res. 34(8), 986-990 (2010).
8. Scheibenbogen C, Letsch A, Thiel E et al.: CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100(6), 2132-2137 (2002).
9. + T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 102(8), 2892-2900 (2003).
10. Oka Y, Tsuboi A, Murakami M et al.: Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int. J. Hematol. 78(1), 56-61 (2003).
11. Oka Y, Tsuboi A, Taguchi T et al.: Induction of WT1 (Wilms' tumor gene)-specific T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA 101(38), 13885-13890 (2004).
12. Rezvani K, Yong AS, Mielke S et al.: Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111(1), 236-22 (2008).
13. Keilholz U, Letsch A, Busse A et al.: A clinical and immunological Phase II trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with MDS and AML. Blood 113(26), 6541-6548 (2009).
14. Narita M, Masuko M, Kurasaki T et al.: WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase. Int. J. Med. Sci 7(2), 72-81 (2010).
15. Ohno S, Kyo S, Myojo S et al.: Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Res. 29(11), 4779-4784 (2009).
16. Izumoto S, Tsuboi A, Oka Y et al: Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma. J. Neurosurg. 108(5), 963-971 (2008).
17. Hashii Y, Sato E, Ohta H et al.: WT1 peptide vaccination for cancer in children and young adults. Pediat. Blood Cancer 26(1), 74-83 (2010).
18. Iiyama T, Udaka K, Takeda S et al.: WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol. Immunol. 51(5), 519-530 (2007).
19. Oka Y, Elisseeva OA, Tsuboi A et al.: Human cytotoxic T lymphocyte responses specific for peptides of wild-type Wilms' tumor gene (W T1) product. Immunogenetics 51(2), 99-107 (2000).
20. + progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95(7), 2198-2203 (2000).
21. + cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95(7), 2198-2203 (2000).
22. Oka Y, Udaka K, Tsuboi A et al.: Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J. Immunol. 164(4), 1873-1880 (2000).
23. Bocchia M, Gentili S, Abruzzese E et al.: Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukemia and persistent residual disease: a multicentre observational trial. Lancet 365(9460), 657-662 (2005).
24. Van Tendeloo VF, Van de Velde A, Van Driessche A et al.: Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigentargeted dendritic cell vaccination. Proc. Natl Acad. Sci. USA 107(31), 13824-13829 (2010).